LDN and Alzheimer’s

Home LDN and Alzheimer’s

NBC News Report Linking Alzheimer’s Disease & CNS Inflammation

Brain (CNS) Inflammation

NBC News recently released an intriguing report that links Alzheimer’s and central nervous system inflammation. If accurate, it is the first truly “attackable” angle to help prevent and potentially mitigate the symptoms of Alzheimer’s.
This may provide opportunities to advance and focus medication development towards neuroinflammation.

What May Lead to Neuroinflammation?

  • Traumatic brain injuries (Concussions, motor vehicle accidents, injury from violence)
  • Autoimmune diseases
  • By-products of diseases- circulating endotoxins
  • Microglial activation- different components to inflammation are led by microglial cells
  • Chronic stress- Chronic stress involves elevated cortisol which can lead to microglial activation via the release of inflammatory cytokines.  In other words, stress often causes chronic inflammation which can lead to neuronal injury or death and therefore changes in behavior. It interferes with all stages of neuronal renewal. Stress causes people to feel scattered and feeling like they can’t think straight. They often wonder what is happening to them.

Low Dose Naltrexone (LDN)

Read about the mechanism in which low dose naltrexone LDN works to reduce inflammation.

Abstract Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone’s better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.

What is Low Dose Naltrexone (LDN)?

Naltrexone belongs to a class of drugs known as opioid antagonists. Naltrexone blocks opiate drugs from binding to the opioid receptors, which can result in increased endorphin and enkephalin release. Therefore, this results in reduced: 1. signaling and release of inflammatory substances, 2. nerve cell inflammation and 3. autoimmune mediators.